Clinical Trial Update: Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of topical diclofenac diethylamine (DDEA) 2.32% gel for knee osteoarthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Diclofenac DDEA 2.32% gel (diclofenac diethylamine 2.32% gel)

Snippet

Sponsor: Novartis | Conditions: Osteoarthritis, Knee | Phase 3 | Status: COMPLETED | Results posted: 2015-06-03